Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Onyx Pharmaceuticals, Inc.

http://www.onyx-pharm.com

Latest From Onyx Pharmaceuticals, Inc.

US FDA Limits GMP Exemption For ‘N of 1’ Investigational New Drugs

Agency drafts guidance on how to apply requirements for chemistry, manufacturing and controls, and for good manufacturing practices, to bespoke antisense nucleotides.

Personalized Medicine Drug Approval Standards

AstraZeneca Boosts Rare Disease Pipeline With Ionis Antisense Candidate

AstraZeneca has bulked up its late-stage pipeline with an agreement for Ionis’s eplontersen which is in trials for two rare diseases, quelling some analysts’ fears about the scarcity of catalysts for next year.

Rare Diseases Deals

Novartis Slips Into Pfizer's Number One Pharma Slot Amid Leaderboard Shakeup

Pfizer has dropped to number seven in our top pharma rankings after a long reign. AbbVie has risen to number three, growing through merger expansion.

Outlook 2022 Commercial

Moderna Shone As COVID-19 Breakthroughs Were Rewarded At The 17th Annual Scrip Awards

The pharma, biotech and allied industries came back together in London on 2 December to celebrate a year of exceptional achievement at the 17th Annual Scrip Awards, hosted by the journalist and broadcaster Amol Rajan.

See All

Company Information

  • Other Names / Subsidiaries
    • Proteolix, Inc.
UsernamePublicRestriction

Register